{"nctId":"NCT00899379","briefTitle":"Treatment of Multiple Attacks of Acute Migraine (0462-025)","startDateStruct":{"date":"1995-04"},"conditions":["Migraine Headache"],"count":473,"armGroups":[{"label":"Treatment Sequence 1","type":"EXPERIMENTAL","interventionNames":["Drug: rizatriptan benzoate","Drug: Comparator: Placebo"]},{"label":"Treatment Sequence 2","type":"EXPERIMENTAL","interventionNames":["Drug: rizatriptan benzoate","Drug: Comparator: Placebo"]},{"label":"Treatment Sequence 3","type":"EXPERIMENTAL","interventionNames":["Drug: rizatriptan benzoate","Drug: Comparator: Placebo"]},{"label":"Treatment Sequence 4","type":"EXPERIMENTAL","interventionNames":["Drug: rizatriptan benzoate","Drug: Comparator: Placebo"]},{"label":"Treatment Sequence 5","type":"EXPERIMENTAL","interventionNames":["Drug: rizatriptan benzoate"]}],"interventions":[{"name":"rizatriptan benzoate","otherNames":["MK0462"]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient had at least a 6-month history of migraine, with or without aura\n* Patient was male, or if female must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions.\n* Patient was judged to be in good health, apart from migraine\n\nExclusion Criteria:\n\n* Patient was pregnant or a nursing mother.\n* Patient had abused drugs or alcohol within 12 months prior to entering the study\n* Patient had a history of cardiovascular disease\n* Patient had clinically significant ECG abnormality\n* Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening\n* Patient received treatment with an investigational device or compound within 30 days of the study start\n* Patient typically suffered from less then 1 or more than 8 attacks of migraine per month\n* Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches\n* Patient had prior exposure to rizatriptan","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain Relief at 2 Hours During the First Migraine Attack Period","description":"Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) at baseline to grades 0 or 1 (no headache or mild) at 2 hours after initial dosing for the first migraine attack","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"246","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Relief at 2 Hours During the Second Migraine Attack Period","description":"Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the second migraine attack","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"228","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Relief at 2 Hours During the Third Migraine Attack Period","description":"Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the third migraine attack","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Relief at 2 Hours During the Fourth Migraine Attack Period","description":"Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the fourth migraine attack","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":337},"commonTop":["Dizziness","Somnolence","Nausea","Asthenia/Fatigue","Paresthesia"]}}}